Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) and Celularity (NASDAQ:CELU – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Profitability
This table compares Arcadia Biosciences and Celularity’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arcadia Biosciences | -195.94% | -113.73% | -68.47% |
| Celularity | -345.45% | N/A | -77.94% |
Valuation and Earnings
This table compares Arcadia Biosciences and Celularity”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arcadia Biosciences | $4.76 million | 0.40 | -$2.34 million | ($5.73) | -0.16 |
| Celularity | $26.55 million | 1.17 | -$91.72 million | ($3.33) | -0.32 |
Arcadia Biosciences has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Arcadia Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 8.2% of Arcadia Biosciences shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Arcadia Biosciences and Celularity, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arcadia Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| Celularity | 1 | 0 | 1 | 0 | 2.00 |
Celularity has a consensus target price of $6.00, suggesting a potential upside of 460.75%. Given Celularity’s stronger consensus rating and higher possible upside, analysts plainly believe Celularity is more favorable than Arcadia Biosciences.
Risk and Volatility
Arcadia Biosciences has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Summary
Celularity beats Arcadia Biosciences on 9 of the 14 factors compared between the two stocks.
About Arcadia Biosciences
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
About Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
